

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Olmstead et al. Serial No.: 09/991,258

Confirmation No.: 4473 Group Art Unit: 1642

Filed: November 16, 2001

Alphavirus Vectors and Virosomes with Modified HIV Genes for Use

in Vaccines

Date: April 16, 2003

Commissioner for Patents Washington, DC 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

For:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,

Mary of Rille

Mary L. Miller

Registration No. 39,303

20792

PATENT TRADEMARK OFFICE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231on April 16, 2003.

Monica L. Croom

6.26.03

RECEIVED TOO THE THE TOO TOO TO THE TOO THE TOO TO THE TOO THE TOO TO THE TOO THE TOO TO THE TOO THE TOO TO THE TOO TO THE TOO TO THE TOO TO THE TOO THE